MARKET

AMPH

AMPH

Amphastar Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

19.08
+0.10
+0.53%
After Hours: 19.08 0 0.00% 16:00 05/12 EDT
OPEN
18.96
PREV CLOSE
18.98
HIGH
19.44
LOW
18.96
VOLUME
180.59K
TURNOVER
--
52 WEEK HIGH
22.69
52 WEEK LOW
16.91
MARKET CAP
908.88M
P/E (TTM)
380.08
1D
5D
1M
3M
1Y
5Y
EQS-Adhoc: Cosmo Pharmaceuticals announces a change in its board of directors
EQS Group-Ad-hoc: Cosmo Pharmaceuticals N.V. / Key word(s): Miscellaneous Cosmo Pharmaceuticals announces a change in its board of directors 10-May-2021 /...
EQS Group AG · 3d ago
DJ Amphastar Pharmaceuticals, Inc. Management on Q1 2021 Results -- Earnings Call Transcript >AMPH
Dow Jones · 3d ago
Amphastar Pharmaceuticals Stock Is Estimated To Be Modestly Undervalued
GuruFocus News · 4d ago
Amphastar to restructure its Chinese subsidiaries
Amphastar Pharmaceuticals (AMPH) announced its decision to buy back 26% of the equity of its subsidiary Amphastar Nanjing Pharmaceuticals ((ANP)).Additionally, ANP will spin off its Chinese subsidiary, Nanjing Hanxin Pharmaceutical (Hanxin), and
Seekingalpha · 5d ago
10-Q: AMPHASTAR PHARMACEUTICALS, INC.
(EDGAR Online via COMTEX) -- ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following is a discussion and...
Edgar Online - (EDG = 10Q, 10K) · 5d ago
BRIEF-Amphastar Announces Buyback Of 26% Of The Equity In Its Anp Subsidiary And Spin-Off Its Hanxin Subsidiary
reuters.com · 5d ago
Amphastar Pharma Reports Buyback Of 26% Of Its Equity In Its ANP Subsidiary; ANP Will Spin Off Its Chinese Subsidiary, Nanjing Hanxin Pharma Technology Co.
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced the restructuring of its Chinese subsidiaries, primarily Amphastar Nanjing Pharmaceuticals Inc. (“ANP”). As part of the restructuring, Amphastar will
Benzinga · 5d ago
Amphastar Announces Buyback of 26% of the Equity in its ANP Subsidiary and Spin-off its Hanxin Subsidiary
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced the restructuring of its Chinese subsidiaries, primarily Amphastar Nanjing Pharmaceuticals Inc. ("ANP"). As part of the restructuring, Amphastar will buyback 26% of ANP's equity currently held by thi...
GlobeNewswire · 5d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AMPH. Analyze the recent business situations of Amphastar Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AMPH stock price target is 21.60 with a high estimate of 25.00 and a low estimate of 19.00.
EPS
Institutional Holdings
Institutions: 187
Institutional Holdings: 29.68M
% Owned: 62.31%
Shares Outstanding: 47.64M
TypeInstitutionsShares
Increased
42
1.47M
New
10
99.86K
Decreased
53
1.17M
Sold Out
16
582.04K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
0.00%
Pharmaceuticals & Medical Research
-0.35%
Key Executives
Chairman/Chief Operating Officer/Director
Mary Luo
President/Chief Executive Officer/Chief Scientific Officer/Director
Jack Zhang
Chief Financial Officer/Senior Vice President/Treasurer
William Peters
Executive Vice President
Rong Zhou
Senior Vice President/Director of Sales/Director of Marketing/Secretary
Jacob Liawatidewi
Lead Director/Independent Director
Richard Prins
Director
Diane Gerst
Independent Director
Richard Koo
Independent Director
Howard Lee
Independent Director
Floyd Petersen
Independent Director
Michael Zasloff
No Data
  • All
  • Financials
  • Insiders
More
About AMPH
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products. The finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, Cortrosyn, Amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes recombinant human insulin and porcine insulin. The Company also manufactures and sells insulin API. As of December 31, 2016, the Company manufactured and sold 19 products. As of December 31, 2016, the Company developed a portfolio of 15 generic abbreviated new drug applications (ANDAs) three generic biosimilar product candidates and six injectable and inhalation product candidates.

Webull offers kinds of Amphastar Pharmaceuticals Inc stock information, including NASDAQ:AMPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMPH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AMPH stock methods without spending real money on the virtual paper trading platform.